
    
      Local treatment included surgical resection, stereotactic body radiotherapy, palliative
      radiotherapy, and radiofrequency ablation. Stereotactic body radiotherapy is preferred as a
      radiation modality.

      Endocrine therapies with/without target therapy including CDK4/6 inhibitors or mTOR
      inhibitors are the mainstay of 1st line treatment for ER-positive/HER2-negative metastatic
      breast cancer.
    
  